. Rolling submission of BLA to the FDA completed for ciltacabtagene autoleucel (cilta-cel) for the treatment of relapsed or refractory multiple myeloma (RRMM) . European Marketing Authorisation Application (MAA) submitted for cilta-cel for the treatment of RRMM . New and updated cilta-cel data to be presented at the upcoming 2021 American Society of Clinical Oncology […]

Longer term follow-up data from the pivotal CARTITUDE-1 study of cilta-cel in heavily pretreated patients with relapsed or refractory multiple myeloma The first presentation of data from the CARTITUDE-2 study of cilta-cel in earlier lines of multiple myeloma treatment SOMERSET, N.J.— (BUSINESS WIRE)—May 12, 2021—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in […]

Submission follows accelerated assessment granted by the Committee for Medicinal Products for Human Use of the European Medicines Agency of the application based on positive Phase 1b/2 CARTITUDE-1 study data SOMERSET, N.J., April 30, 2021 – Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of […]

Legend received approximately $659.8 million in gross proceeds through share capital increases during 2020, including a successful Nasdaq IPO with aggregate gross proceeds of $487.3 million. U.S. FDA clearance for IND application for a Phase 1 clinical trial to evaluate LB1901 in relapsed or refractory T-cell lymphoma (RR TCL). Rolling submission of BLA to the […]

SOMERSET, N.J., March 10, 2021 – Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, will release its fourth quarter and full-year 2020 financial results before U.S. financial markets open on Thursday, March 18, 2021. Legend Biotech […]